PHARMACEUTICAL COMPOSITION FOR TREATING MUSCLE-INVASIVE BLADDER CANCER, CONTAINING S100A9 AND EGFR INHIBITORS AND CISPLATIN AS ACTIVE INGREDIENTS

摘要

The present invention relates to a method for predicting the probability of muscle-invasive bladder cancer (MIBC) recurrence or metastasis, a method for providing information on a personalized medicine of MIBC, and a pharmaceutical composition for treating MIBC, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients. According to the present invention, it is possible to accurately predict a prognosis after chemotherapy of an MIBC patient, to provide information on cisplatin sensitivity in the provision of a personalized medicine for chemotherapy of an MIBC patient, and to increase the cisplatin sensitivity of an MIBC patient by concomitantly administering S100A9 and EGFR inhibitors together with a conventional cisplatin.